Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Combined With Anlotinib in Thymoma and Thymic Carcinoma
NCT06838910Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab and anlotinib in thymoma and thymic carcinoma (TC), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Objective Response Rate at 2 years. Started Mar 2025; status: recruiting.
02
Drugs
tislelizumabanlotinib
03
Conditions
thymomathymic carcinoma (TC)
Beyond the preview
Go deeper on NCT06838910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06838910.